Burning Rock Biotech (BNR) Cost of Revenue (2019 - 2026)

Burning Rock Biotech's Cost of Revenue history runs 8 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 11.77% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $18.6 million (down 10.32% YoY), while the FY2025 annual figure was $19.5 million, down 7.03% from the prior year.
• Cost of Revenue for Q1 2026 stood at $4.3 million, up from $4.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $7.6 million in Q1 2022, with the low at $4.0 million in Q4 2025.
• The 5-year median for Cost of Revenue is $5.6 million (2025), against an average of $5.7 million.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue jumped 66.95% in 2022, then dropped 20.86% in 2025.
• Burning Rock Biotech's Cost of Revenue stood at $5.9 million in 2022, then advanced by 1.89% to $6.1 million in 2023, then fell by 17.15% to $5.0 million in 2024, then retreated by 20.86% to $4.0 million in 2025, then increased by 9.35% to $4.3 million in 2026.
• Business Quant data shows BNR's Cost of Revenue at $4.3 million in Q1 2026, $4.0 million in Q4 2025, and $4.6 million in Q3 2025.